125 related articles for article (PubMed ID: 32348852)
21. Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Quaas A; Heydt C; Waldschmidt D; Alakus H; Zander T; Goeser T; Kasper P; Bruns C; Brunn A; Roth W; Hartmann N; Bunck A; Schmidt M; Buettner R; Merkelbach-Bruse S
BMC Gastroenterol; 2019 Feb; 19(1):21. PubMed ID: 30717682
[TBL] [Abstract][Full Text] [Related]
22. ESR1 fusions and therapeutic resistance in metastatic breast cancer.
Nagy Z; Jeselsohn R
Front Oncol; 2022; 12():1037531. PubMed ID: 36686845
[TBL] [Abstract][Full Text] [Related]
23. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
[TBL] [Abstract][Full Text] [Related]
24. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
[TBL] [Abstract][Full Text] [Related]
25. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
26.
Vahdatinia M; Derakhshan F; Da Cruz Paula A; Dopeso H; Marra A; Gazzo AM; Brown D; Selenica P; Ross DS; Razavi P; Zhang H; Weigelt B; Wen HY; Brogi E; Reis-Filho JS; Pareja F
J Clin Pathol; 2023 Dec; 77(1):40-45. PubMed ID: 36323507
[TBL] [Abstract][Full Text] [Related]
27. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.
Zhu VW; Klempner SJ; Ou SI
Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287
[TBL] [Abstract][Full Text] [Related]
28. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
[TBL] [Abstract][Full Text] [Related]
29. The genetic landscape of ganglioglioma.
Pekmezci M; Villanueva-Meyer JE; Goode B; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Chamyan G; Maher OM; Khatib Z; Kleinschmidt-DeMasters BK; Samuel D; Mueller S; Banerjee A; Clarke JL; Cooney T; Torkildson J; Gupta N; Theodosopoulos P; Chang EF; Berger M; Bollen AW; Perry A; Tihan T; Solomon DA
Acta Neuropathol Commun; 2018 Jun; 6(1):47. PubMed ID: 29880043
[TBL] [Abstract][Full Text] [Related]
30. Clinical Utility of Cell-Free DNA for the Detection of
McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
[No Abstract] [Full Text] [Related]
31. A Comparison of Morphologic and Molecular Features of BRAF, ALK, and NTRK1 Fusion Spitzoid Neoplasms.
Amin SM; Haugh AM; Lee CY; Zhang B; Bubley JA; Merkel EA; Verzì AE; Gerami P
Am J Surg Pathol; 2017 Apr; 41(4):491-498. PubMed ID: 27776007
[TBL] [Abstract][Full Text] [Related]
32. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.
Zhang S; Yan B; Zheng J; Zhao J; Zhou J
Oncotarget; 2016 Sep; 7(39):63758-63766. PubMed ID: 27563816
[TBL] [Abstract][Full Text] [Related]
33. The role of gene fusions in melanocytic neoplasms.
Quan VL; Panah E; Zhang B; Shi K; Mohan LS; Gerami P
J Cutan Pathol; 2019 Nov; 46(11):878-887. PubMed ID: 31152596
[TBL] [Abstract][Full Text] [Related]
34. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
35. Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors.
Xu H; Shen J; Xiang J; Li H; Li B; Zhang T; Zhang L; Mao X; Jian H; Shu Y
Cancer Manag Res; 2019; 11():6343-6351. PubMed ID: 31372039
[No Abstract] [Full Text] [Related]
36. Identification and characterization of RET fusions in advanced colorectal cancer.
Le Rolle AF; Klempner SJ; Garrett CR; Seery T; Sanford EM; Balasubramanian S; Ross JS; Stephens PJ; Miller VA; Ali SM; Chiu VK
Oncotarget; 2015 Oct; 6(30):28929-37. PubMed ID: 26078337
[TBL] [Abstract][Full Text] [Related]
37. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
Ji JH; Oh YL; Hong M; Yun JW; Lee HW; Kim D; Ji Y; Kim DH; Park WY; Shin HT; Kim KM; Ahn MJ; Park K; Sun JM
PLoS Genet; 2015 Aug; 11(8):e1005467. PubMed ID: 26295973
[TBL] [Abstract][Full Text] [Related]
38. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.
Paoletti C; Cani AK; Larios JM; Hovelson DH; Aung K; Darga EP; Cannell EM; Baratta PJ; Liu CJ; Chu D; Yazdani M; Blevins AR; Sero V; Tokudome N; Thomas DG; Gersch C; Schott AF; Wu YM; Lonigro R; Robinson DR; Chinnaiyan AM; Bischoff FZ; Johnson MD; Park BH; Hayes DF; Rae JM; Tomlins SA
Cancer Res; 2018 Feb; 78(4):1110-1122. PubMed ID: 29233927
[TBL] [Abstract][Full Text] [Related]
40. The landscape and therapeutic relevance of cancer-associated transcript fusions.
Yoshihara K; Wang Q; Torres-Garcia W; Zheng S; Vegesna R; Kim H; Verhaak RG
Oncogene; 2015 Sep; 34(37):4845-54. PubMed ID: 25500544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
